Abstract
The globalization of the biopharmaceutical industry over the past 15 years has provided unprecedented opportunity for laboratories and research organizations to tap into new geographies and extend the scope of clinical trials and studies. At the same time, pressing biosafety issues that potentially put at risk both those handling the specimens and the public at large, has led to a profusion of directives—and sometimes conflicting information—from within the industry, governmental bodies, regulatory agencies, and transporters themselves.